Winners

摘要

Health insurers dodged the "public option" bullet and have been enjoying higher profits since the law passed, with the largest U.S. insurers beating the consensus forecast of Wall Street analysts in every quarter since the start of 2009, according to a Bloomberg Government study. Still to come (if the Supreme Court allows it): millions of new customers required by the law to buy health coverage. Drug and biotech companies spent $150 million lobbying in support of the health-care overhaul and got their money's worth. The pharmaceutical industry accepted $80 billion in projected reimbursement cuts over 10 years in exchange for greatly expanded numbers of insured Americans. More insured patients will likely mean more visits to doctors, who will write more prescriptions. Brand names also got more protections against generics.